**Supplementary Table S5.** Cost-effectiveness results for pembrolizumab plus chemotherapy (weighted average) vs. chemotherapy (weighted average)

| **Outcomes** | **Pembrolizumab plus chemotherapy (weighted average)** | **Chemotherapy (weighted average)** | | **Pembrolizumab plus chemotherapy (weighted average) vs. Chemotherapy (weighted average)** |
| --- | --- | --- | --- | --- |
| **Costs ($)** |  |  | |  |
| Total costs | **$283,882** | **$150,415** | | **$133,468** |
| Regimen-related costs | $136,371 | $27,651 | | $108,721 |
| Drug acquisition costs | $130,099 | $23,705 | | $106,394 |
| Drug administration costs | $5,811 | $3,945 | | $1,865 |
| Testing costs | $461 | $0 | | $461 |
| Subsequent therapy costs | $11,873 | $23,204 | | −$11,331 |
| AE management costs | $2,262 | $1,842 | | $419 |
| Disease management costs | $133,376 | $97,717 | | $35,659 |
| **Effectiveness** |  |  | |  |
| Total QALY | **2.413** | **1.677** | | **0.736** |
| Total LY | **3.008** | **2.125** | | **0.883** |
| Progression-free | 2.014 | 1.007 | | 1.007 |
| Progressive disease | 0.994 | 1.118 | | −0.124 |
| **Incremental cost-effectiveness ratio ($)** |  |  | |  |
| Incremental cost per QALY gained |  | | | $181,383 |
| Incremental cost per LY gained |  | | $151,215 | |

**Abbreviations:** AE, adverse event; LY: life years, QALY: quality-adjusted life year.